CDSCO Form 12A vs Form 10 vs Form 11, India

What this pathway is

Form 12A is the personal-import licence for a named patient; Form 10 and Form 11 are commercial-import licences. Mixing them up is the most common India access mistake. This guide explains the legal basis of the pathway, the documents the regulator expects, the typical timeline, the costs that fall on the patient versus the hospital, and the failure modes that most often delay or block an approval.

Legal basis

Most countries operate two parallel access regimes: a personal-import route for individual patients with a named indication, and a hospital or institutional route for cohorts or programmes. The legal basis differs. Personal import typically sits inside the country's drugs and cosmetics act or equivalent; hospital exemption typically sits inside the hospital's compounding or unlicensed-medicines authority. Conflating the two is the most common reason a regulator rejects a file.

Documents the regulator wants

The standard package includes a treating-physician declaration that the drug is necessary and that no registered alternative is suitable, a prescription written by a locally licensed physician, the patient's national-ID or passport, an invoice or quote, an import declaration, and in some jurisdictions an ethics-committee letter. Some regulators add language requirements; UAE accepts English, KSA prefers Arabic with an English appendix, India accepts English, EU member states vary by country.

Typical timeline

Patient-named pathways in MENA process in 7-21 days; India typically 14-30; EU compassionate use varies by member state, with Germany and France faster than the average, and several Eastern European jurisdictions slower. The fastest known files move when the treating physician, the regulator and the importer share a single document set, with named contacts on each side and a clean indication letter.

Costs that fall on the patient

Patients usually pay the drug, the cold-chain handling, the customs duty, the broker fee, and any local hospital-pharmacy receipt fee. Patients rarely pay a regulator fee directly; that is typically absorbed by the importer or by the hospital. In countries with a sovereign or charitable fund, the patient may pay nothing, and the importer invoices the fund directly.

What can go wrong

Three patterns recur. First, an indication mismatch: the drug is approved in the source country for one indication and being imported for another, and the regulator wants a treating-physician letter that specifically addresses that gap. Second, a documentation gap: a missing translation or attestation that delays the file by 5-10 business days. Third, a cold-chain or customs hold: the drug arrives but is detained at the port because the broker did not pre-clear the regulator licence. All three are preventable.

What a clean file looks like

A clean file lists the drug by INN and brand name, references the manufacturer and lot, names the patient with full date-of-birth and ID, names the treating physician with licence number, attaches the prescription, the patient's diagnosis with ICD-10 code, the treating-physician declaration, and the importer's authorisation. Where applicable, the file attaches an ethics-committee letter and a customs pre-clearance reference. When all of these are in the same PDF in the order the regulator expects, approval is usually procedural.

How Reserve Meds works inside this pathway

Reserve Meds prepares the documentation pack against the destination regulator's published checklist, with a US-source-side invoice and DSCSA paperwork, and routes the package to the treating physician for filing. We do not act as the legal importer in countries where the regulator requires a locally licensed entity; we coordinate with the locally licensed importer of record. Our role is operational: a clean file, on time, with the right attachments.

Frequently asked questions

Do I need a local prescription?

Almost always yes. Most regulators require a prescription from a physician licensed in the destination country, in addition to any US prescription used for sourcing.

How long does the pathway take?

Most patient-named pathways in MENA process in 7-21 days; India typically 14-30; EU compassionate use varies by member state and can take 30-60 days.

Will the regulator inspect my package?

Customs may. Regulators rarely inspect personal-import quantities, but they retain that right; complete documentation prevents most delays.

Related on Reserve Meds

• Drug catalog
• Conditions
• Access pathways
• Countries
• Access guides
• UAE pathway
• India pathway
• KSA pathway

Sources

• CDSCO - Central Drugs Standard Control Organization
• Saudi Food and Drug Authority
• UAE Ministry of Health and Prevention
• PMDA - Pharmaceuticals and Medical Devices Agency, Japan

Start a request

Start a request